Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : GILD save search
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
Published: 2022-02-18 (Crawled : 18:00) - prnewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.18%
H: 0.42%
C: -0.57%
treatment europe disease preclinical potential pre-clinical
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published: 2021-12-07 (Crawled : 10:00) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
europe covid covid-19
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Published: 2021-11-15 (Crawled : 16:00) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 0.34%
H: 1.74%
C: -0.4%
treatment europe ulcerative colitis
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
Published: 2021-08-19 (Crawled : 23:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.49%
H: 1.01%
C: 0.08%
treatment europe therapy hiv authorized xin
Gilead Sciences to Acquire MYR GmbH
Published: 2020-12-10 (Crawled : 14:01) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.26%
H: 0.39%
C: -0.35%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.